Amicus Therapetics – Ground-Breaking Medicines

Amicus Therapeutics, is a global biotechnology company currently in the works for producing highly effective medicines for those people living in rare and devastating conditions of many uncomfortable genetic diseases. So many innovative medicines are currently in development to pioneer the medicine industry and change the world forever. From the Fabry disease to the Epidermolysis Bullosa skin disorder, Amicus Therapeutics is set to relieve a lot of concerned and worried individuals in our ever so diverse world of today! The goal of the company is to make a meaningful difference in the lives of patients. With these up and coming solutions, Amicus is definitely on the right track to an unbelievable break-through!

Founded in 2002, with current assets right around $128 Million, this Cranbury, New Jersey company resides in the pharmaceutical industry by CEO John Crowley, COO Bradley Campbell and CFO William Baird. With their hard work, vision and helping staff, the company is currently recognized as having the broadest portfolio of small molecule pharmacological chaperones in the industry. Learn more about Amicus Therapeutics at Dial Dish.

Prepare to witness products to hit the market that are captivating and highly effective for the remedy it provides.

Migalastat – this personalized medicine is going to be a highly valuable treatment for those individuals living with Fabry disease. SD-101 – this medicine is going to treat the genetic tissue disorder, Epidermolysis Bullosa. These couple and many other ground-breaking medicines are set to hit the market and best treat the many genetic nightmare causing diseases that consumes our wealthy community! Read more at seekingalpha.com about Amicus Therapeutics.

In addition, the Amicus Therapeutics is consistently improving and enhancing its Chaperone-Advanced Replacement Therapy® platform technologies – a product development program –

to best produce the most effective enzyme replacement therapy necessary for the most successful treatment results for Lysosomal Storage Disorders: Fabry and Pompe diseases.

Stay tuned to Amicus Therapeutic – through their website – for the newest developments for treating rare and devastating genetic diseases. Always be aware of its ingredient containment to best corresponds to your health condition. Experience a breakthrough for a community filled with genetic diseases!

View: http://www.marketwatch.com/investing/stock/fold

Leave a Reply

Your email address will not be published. Required fields are marked *